Literature DB >> 7541349

Presence of an extended duplication in the putative low-density-lipoprotein receptor-binding domain of apolipoprotein B. Cloning and characterization of the domain in salmon.

P J Babin1, F Deryckere, F Gannon.   

Abstract

The sequence of the C-terminal 1058 amino acids of atlantic salmon (Salmo salar) apolipoprotein (apo) B was deduced from the nucleotide sequence of cloned cDNA. In comparison with chicken or mammals apoB-100, salmon apoB is C-terminally truncated and extended gaps are found. The two clusters of positively charged residues, previously identified as part of the putative low-density-lipoprotein (LDL) receptor-binding domain of apoB, are brought into close proximity in salmon apoB. This is achieved by the absence between the two clusters of the proline-rich area with the potential to form an amphipathic beta sheet, present in higher vertebrates. In addition, analysis of apoB amino acid sequences currently available in vertebrates revealed the presence of an extended internal duplication in the putative LDL receptor-binding domain. Thus, the two basic clusters would have been duplicated resulting in the presence, except for salmon apoB, of two homologous sites in the C-terminal part of the molecule. The results described here together with earlier biochemical and genetic evidence support the view that Arg3500, a residue mutated in familial defective apoB-100, could be included in a folded critical region of the putative LDL receptor-binding domain of human apoB-100. This region possibly brings the two sub-domains that arise from the duplication close to each other.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541349     DOI: 10.1111/j.1432-1033.1995.tb20532.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  1 in total

1.  Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda.

Authors:  Chris Ebong; Asadu Sserwanga; Jane Frances Namuganga; James Kapisi; Arthur Mpimbaza; Samuel Gonahasa; Victor Asua; Sam Gudoi; Ruth Kigozi; James Tibenderana; John Bosco Bwanika; Agaba Bosco; Denis Rubahika; Daniel Kyabayinze; Jimmy Opigo; Damian Rutazana; Gloria Sebikaari; Kassahun Belay; Mame Niang; Eric S Halsey; Leah F Moriarty; Naomi W Lucchi; Samaly S Svigel Souza; Sam L Nsobya; Moses R Kamya; Adoke Yeka
Journal:  Malar J       Date:  2021-12-24       Impact factor: 2.979

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.